-
Track & Monitor
Microbiome in pharma: bacteriophage therapy
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s bacteriophage therapy segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based on...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Parkinson’s Disease in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Parkinson's Disease in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Parkinson's Disease in Parkinson's Disease Drug Details: The drug candidate is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Side-effects Of Cancer Chemotherapy in Chemotherapy Effects
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Side-effects Of Cancer Chemotherapy in Chemotherapy Effects report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Side-effects Of Cancer Chemotherapy in Chemotherapy Effects Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MET-5 in Hypertriglyceridemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MET-5 in Hypertriglyceridemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MET-5 in Hypertriglyceridemia Drug Details: MET-5 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MET-2 in Major Depressive Disorder
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MET-2 in Major Depressive Disorder report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MET-2 in Major Depressive Disorder Drug Details: MET-2 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SER-155 in Graft Versus Host Disease (GVHD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SER-155 in Graft Versus Host Disease (GVHD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SER-155 in Graft Versus Host Disease (GVHD) Drug...
-
Thematic Analysis
NewState of the Biopharmaceutical Industry 2024 Edition (Mid-Year Update) – Thematic Intelligence
Although the pharmaceutical industry is often labeled as a recession-resistant, it is not immune to future challenges. Ongoing issues such as constraints on drug pricing and reimbursement (P&R), the evolving regulatory landscape, pressures to innovate, and pressures to address environmental, social, and governance (ESG) issues will continue to pose challenges for the pharmaceutical sector in the coming years. In this “The State of the Biopharmaceutical Industry” report, GlobalData examines the business environment and trends that are going to shape the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VE-303 in Liver Cirrhosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VE-303 in Liver Cirrhosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VE-303 in Liver Cirrhosis Drug Details: VE-303 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – VE-303 in Hepatic Encephalopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VE-303 in Hepatic Encephalopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VE-303 in Hepatic Encephalopathy Drug Details: VE-303 is under development for...